___

• Hu KQ. Occult Hepatitis B Virus Infection and its Clinical Implications. Journal of Viral Hepatitis 2002; 9(4): 243-57.
• Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, ColomboM et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol. 2008; 49: 652-7.
• Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B virus infection. J Hepatol. 2007; 46: 160-70.
• Zobeiri M. Occult Hepatitis B: Clinical Viewpoint and Management. Hindawi Publishing Corporation Hepatitis Research and Treatment Volume 2013, Article ID 259148, (Doi:10.1155/2013/259148).
• Samal J, Kandpal M, Vivekanandan P. Molecular Mechanisms Underlying Occult Hepatitis B Virus Infection. Clin Microbiol Rev. 2012; 25(1): 142-63. (doi:10.1128/ CMR.00018-11).
• Kasapoğlu B, Türkay C. Okült (OCCULT) Hepatit B Enfeksiyonu [Occult Hepatitis B Infection]. Güncel Gastroenteroloji 2007; 11(2): 51-6.
• Altındiş M, Uslan I, Çetinkaya Z, Yüksel Ş, Çiftçi IH, Demirtürk N ve ark. Hemodiyaliz Hastalarının Gizli Hepatit B Varlığı Yönünden Araştırılması [Investigation Of Hemodialysis Patients In Terms Of The Presence Of Occult Hepatıtıs B]. Mikrobiyol Bült. 2007; 41(2): 227-33.
• Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis. 2002; 2(8) :479-86. (doi:10.1016/S1473- 3099(02)00345-6).
• Said ZNA. An overview of occult hepatitis B virus infection. World J Gastroenterol. 2011; 17(15): 1927-38. (doi:10.3748/wjg.v17.i15.1927).
• Raimondo G, Caccamo G, Filomia R, Pollicino T. Occult HBV infection. Semin Immunopatho. 2013; 35: 39-52. (doi 10.1007/s00281-012-0327-7).
• Yuen MF, Wong DK, Lee CK, Tanaka Y, Allain JP, Fung J et al. Transmissibility of hepatitis B virus (HBV) infection through blood transfusion from blood donors with occult HBV infection. Clin Infect Dis. 2011; 52(5): 624-32. (doi:10.1093/cid/ciq247).
• Gerlich WH, Bremer C, Saniewski M, Schüttler CG, Wend UC, Willems WR et al. Occult Hepatitis B Virus Infection: Detection and Significance. Dig Dis. 2010; 28(1): 116-25. (doi:10.1159/000282074).
• Candotti D, Allain JP. Transfusion-transmitted hepatitis B virus infection. J Hepatol. 2009; 51: 798-809.
• Komiya Y, Katayama K, Yugi H, Mizui M, Matsukura H, Tomoguri T et al. Minimum infectious dose of hepatitis B virus in chimpanzees and difference in the dynamics of viremia between genotype A and genotype C. Transfusion 2008; 48: 286-94.
• Bouike Y, Imoto S, Mabuchi O, Kokubunji A, Kai S, Okada M et al. Infectivity of HBV DNA positive donations identified in look-back studies in Hyogo-Prefecture, Japan. Transfus Med. 2011; 21: 107-15.
• Satake M, Taira R, Yugi H, Hino S, Kanemitsu K, Ikeda H et al. Infectivity of blood components with low hepatitis B virus DNA levels identified in a lookback program. Transfusion 2007; 47: 1197-205.
• Levicnik-Stezinar S, Rahne-Potokar U, Candotti D, Lelie N, Allain JP. Anti-HBs positive occult hepatitis B virus carrier blood infectious in two transfusion recipients. J Hepatol. 2008; 48: 1022-5.
• Prince AM, Lee DH, Brotman B. Infectivity of blood from PCR-positive, HBsAg-negative, anti-HBs-positive cases of resolved hepatitis B infection. Transfusion 2001; 41: 329-32.
• Su TH, Chen PJ, Chen TC, Cheng HR, Li L, Lin KS et al. The clinical significance of occult hepatitis B transfusion in Taiwan-a look-back study. Transfus Med. 2011; 21: 33-41.
• Cholongitas E, Papatheodoridis GV, Burroughs AK. Liver grafts from anti-hepatitis B core positive donors: a systematic review. J Hepatol. 2010; 52: 272-9.
• Barcena R, Moraleda G, Moreno J, Martín MD, de Vicente E, Nuño J et al. Prevention of de novo HBV infection by the presence of anti-HBs in transplanted patients receiving core antibody-positive livers. World J Gastroenterol. 2006; 12: 2070-4.
• Coffin CS, Mulrooney-Cousins PM, van Marle G, Roberts JP, Michalak TI, Terrault NA. Hepatitis B virus quasispecies in hepatic and extrahepatic viral reservoirs in liver transplant recipients on prophylactic therapy. Liver Transpl. 2011; 17: 955-62.
• Angelico M, Nardi A, Marianelli T, Caccamo L, Romagnoli R, Tisone G et al. Hepatitis B-core antibody positive donors in liver transplantation and their impact on graft survival: evidence from the Liver Match cohort study. J Hepatol. 2013; 58(4): 715-23. (doi: 10.1016/j.jhep.2012.11.025).
• Strasser SI, McDonald GB. Hepatitis viruses and hematopoietic cell transplantation: A guide to patient and donor management. Blood 1999; 93: 1127-36.
• Satterthwaite R, Ozgu I, Shidban H, Aswad S, Sunga V, Zapanta R Jr et al. Risks of transplanting kidneys from hepatitis B surface antigen-negative, hepatitis B core antibody-positive donors. Transplantation 1997; 64: 432-5.
• Pinney SP, Cheema FH, Hammond K, Chen JM, Edwards NM, Mancini D. Acceptable recipient outcomes with the use of hearts from donors with hepatitis-B core antibodies. J Heart Lung Transplant. 2005; 24: 34-7.
• Kanbay M, Gur G, Akcay A, Selcuk H, Yilmaz U, Arslan H. Is hepatitis C virus positivity a contributing factor to occult hepatitis B virus infection in hemodialysis patients?. Dig Dis Sci. 2006; 51(11): 1962-6. (doi:10.1007/s10620-006-9421-9).
• Di Stefano M, Volpe A, Stallone G, Tartaglia L, Prato R, Martinelli D et al. Occult HBV infection in hemodialysis setting is marked by presence of isolated antibodies to HBcAg and HCV. J Nephrol. 2009; 22: 381-6.
• Pollicino T, Belloni L, Raffa G, Pediconi N, Squadrito G, Raimondo G et al. Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNAbound H3 and H4 histones. Gastroenterology 2006; 130: 823-37.
• Hoofnagle JH. Reactivation of hepatitis B. Hepatology 2009; 49(5): 156-65.
• Papamichalis P, Alexiou A, Boulbou M, Dalekos GN, Rigopoulou EI. Reactivation of resolved hepatitis B virus infection after immunosuppression: is it time to adopt preemptive therapy?. Clinics and Research in Hepatology and Gastroenterology 2012; 36(1): 84-93.
• Watanabe M, Shibuya A, Tsunoda Y, Danbara M, Ishii R, Ohsaka M et al. Re-appearance of hepatitis B virus following therapy with rituximab for lymphoma is not rare in Japanese patients with past hepatitis B virus infection. Liver Int. 2011; 31(3): 340-7. (doi: 10.1111/j.1478-3231.2010.02417.x).
• Knöll A, Pietrzyk M, Loss M, Goetz WA, Jilg W. Solid-organ transplantation in HBsAg-negative patients with antibodies to HBV core antigen: Low risk of HBV reactivation. Transplantation 2005; 79(11): 1631-3.
• Larrubia JR, Lled´o JL, Fern´andez C, Guti´errez ML, Oca~na S. Management of occult hepatitis B virus infection: an update for the clinician. World J Gastroenterol. 2011; 17(12): 1563-8.
• Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008; 2(3): 263-83. (doi: 10.1007/s12072-008-9080-3).
• Fang Y, Shang QL, Liu JY, Li D, Xu WZ, Teng X et al. Prevalence of occult hepatitis B virus infection among hepatopathy patients and healthy people in China. J Infect. 2009; 58(5): 383-8. (doi: 10.1016/j.jinf.2009.02.013).
• Blackberg J, Kidd-Ljunggren K. Occult hepatitis B virus after acute self-limited infection persisting for 30 years without sequence variation. J Hepatol. 2000; 33: 992-7.
• Yuen MF, Lee CK, Wong DK, Fung J, Hung I, Hsu A, But DY et al. Prevalence of occult hepatitis B infection in a highly endemic area for chronic hepatitis B: a study of a large blood donor population. Gut 2010; 59(10): 1389-93. (doi: 10.1136/ gut.2010.209148).
• Raimondo G, Pollicino T, Squadrito G. What is the clinical impact of occult hepatitis B virus infection? Lancet 2005; 365: 638-40.
• Squadrito G, Spinella R, Raimondo G. The clinical significance of occult HBV infection. Ann Gastroenterol. 2014; 27: 1-5.
• Fabris P, Brown D, Tositti G, Bozzola L, Giordani MT, Bevilacqua P et al. Occult hepatitis B infection does not affect liver histology or response to therapy with interferon alpha and ribavirin in intravenous drug users with chronic hepatitis C. J Clin Virol. 2004; 29: 160-6.
• Matsuoka S, Nirei K, Tamura A, Nakamura H, Matsumura H, Oshiro S et al. Influence of occult hepatitis B virus coinfection on the incidence of fibrosis and hepatocellular carcinoma in chronic hepatitis C. Intervirology 2008; 51: 352-61.
• Kannangai R, Vivekanandan P, Netski D, Mehta S, Kirk GD, Thomas DL et al. Liver enzyme flares and occult hepatitis B in persons with chronic hepatitis C infection. J Clin Virol. 2007; 39: 101-5.
• Miura Y, Shibuya A, Adachi S, Takeuchi A, Tsuchihashi T, Nakazawa T et al. Occult hepatitis B virus infection as a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C in whom viral eradication fails. Hepatol Res. 2008; 38: 546-56
• Squadrito G, Cacciola I, Alibrandi A, Pollicino T, Raimondo G. Impact of occult hepatitis B virus infection on the outcome of chronic hepatitis C. J Hepatol. 2013; 59: 696-700.
• Nirei K, Kaneko M, Moriyama M, Arakawa Y. The clinical features of chronic hepatitis C are not affected by the coexistence of hepatitis B virus DNA in patients negative for hepatitis B surface antigen. Intervirology. 2000; 43: 95-101.
• Caviglia GP, Abate ML, Manzini P, Danielle F, Ciancio A, Rosso C et al. Occult Hepatitis B Virus Infection in Patients With Chronic Hepatitis C Treated With Antiviral Therapy. Hepat Mon. 2012; 12(11): e7292. (doi: 10.5812/hepatmon.7292).
• Castillo I, Rodriguez-Inigo E, Lopez-Alcorocho JM, Bartolome J, Pardo M, Carreno V. Comparative study on the clinical and virological characteristics among patients with single occult hepatitis B virus (HBV), single occult hepatitis C virus (HCV) and occult HBV and HCV dual infection. J Med Virol. 2007; 79: 236-41.
• Yotsuyanagi H, Shintani Y, Moriya K, Fujie H, Tsutsumi T, Kato T et al. Virologic analysis of non-B, non-C hepatocellular carcinoma in Japan: frequent involvement of hepatitis B virus. J Infect Dis. 2000; 181(6): 1920-8.
• Ikeda K, Kobayashi M, Someya T, Saitoh S, Hosaka T, Akuta N et al. Occult hepatitis B virus infection increases hepatocellular carcinogenesis by eight times in patients with non-B, non-C liver cirrhosis: a cohort study. J Viral Hepat. 2009; 16(6): 437-43. (doi: 10.1111/j.1365-2893.2009.01085.x).
• Shi Y, Wu YH, Wu W, Zhang WJ, Yang J, Chen Z. Association between occult hepatitis B infection and the risk of hepatocellular carcinoma: a meta-analysis. Liver Int. 2012; 32: 231-40.
• Demir M, Serin E, Göktürk S, Ozturk NA, Kulaksizoglu S, Ylmaz U. The prevalence of occult hepatitis B virus infection in type 2 diabetes mellitus patients. Eur J Gastroenterol Hepatol. 2008; 20: 668-73.
• Pollicino T, Saitta C, Raimondo G. Hepatocellular carcinoma: the point of view of the hepatitis B virus. Carcinogenesis 2011; 32: 1122-32.
• Fwu CW, Chien YC, Kirk GD, Nelson KE, You SL, Kuo HS et al. Hepatitis B virus infection and hepatocellular carcinoma among parous Taiwanese women: nationwide cohort study. J Natl Cancer Inst. 2009; 101: 1019-27.
• Nishikawa H, Osaki Y. Clinical Significance of Occult Hepatitis B Infection in Progression of Liver Disease and Carcinogenesis. J Cancer 2013; 4(6): 473-80. (doi:10.7150/ jca.6609).
• Covolo L, Pollicino T, Raimondo G, Donato F. Occult hepatitis B virus and the risk for chronic liver disease: a meta-analysis. Dig Liver Dis. 2013; 45(3): 238-44.
• Arababadi MK, Nasiri Ahmadabadi B, Kennedy D. Current information on the immunologic status of occult hepatitis B infection. Transfusion 2012; 52(8): 1819-26.
• Wang Y, Yang S, Song F, Cao S, Yin X, Xie J et al. Hepatitis B virus status and the risk of pancreatic cancer: a meta-analysis. Eur J Cancer Prev. 2013; 22(4): 328-34. (doi: 10.1097/ CEJ.0b013e32835b6a21).
• Liu WP, Zheng W, Wang XP, Song YQ, Xie Y, Tu MF et al. An analysis of hepatitis B virus infection rate in 405 cases of non-Hodgkin lymphoma. Zhonghua Xue Ye Xue Za Zhi. 2011; 32(8): 521-4.
• Perumal V, Wang J, Thuluvath P, Choti M, Torbenson M. Hepatitis C and hepatitis B nucleic acids are present in intrahepatic cholangiocarcinomas from the United States. Hum Pathol. 2006; 37: 1211-6.
• Rossi D, Sala L, Minisini R, Fabris C, Falleti E, Cerri M et al. Occult hepatitis B virus infection of peripheral blood mononuclear cells among treatment-naive patients with chronic lymphocytic leukemia. Leuk Lymphoma 2009; 50: 604-11.
• Torresi J, Earnest-Silveira L, Civitico G, Walters TE, Lewin SR, Fyfe J et al. Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the "fingers" subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene. Virology 2002; 299(1): 88-99.
• Biswas R, Tabor E, Hsia CC, Wright DJ, Laycock ME, Fiebiget EW et al. Comparative sensitivity of HBV NATs and HBsAg assays for detection of acute HBV infection. Transfusion 2003; 43(6): 788-98. (doi:10.1046/j.1537-2995.2003.00424.x).
• Satoh K, Iwata Takakura A, Yoshikawa A, Gotanda Y,Tanaka T,Yamaguchi T et al. A new method of concentrating hepatitis B virus (HBV) DNA and HBV surface antigen: an application of the method to the detection of occult HBV infection. Vox Sang. 2008; 95(3): 174-80. (doi:10.1111/j.1423- 0410.2008.01091.x).
• Yuan Q, Ge S, Xiong J, Yan Q, Li Z, Hao X et al. A novel immunoassay for PreS1 and/or core-related antigens for detection of HBsAg variants. J Virol Methods 2010; 168: 108-13.
• Urbani S, Fagnoni F, Missale G, Franchini M. The role of anti- core antibody response in the detection of occult hepatitis B virus infection. Clin Chem Lab Med. 2010; 48: 23-9.
• Guide to the preparation, use and quality assurance of blood components - 17th Edition, European Directorate for Quality of Medicine and Healthcare, 2014.
• Yoshikawa A, Gotanda Y, Minegishi K, Taira R, Hino S, Tadokoro K et al. Lengths of hepatitis B viremia and antigenemia in blood donors: preliminary evidence of occult (hepatitis B surface antigen-negative) infection in the acute stage. Transfusion 2007; 47: 1162-71.